Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

P. R. Bargo, S. L. Jacques

Research output: Contribution to journalConference article

Abstract

The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalProceedings of SPIE - The International Society for Optical Engineering
Volume4257
DOIs
StatePublished - Jan 1 2001
EventLaser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical - San Jose, CA, United States
Duration: Jan 21 2001Jan 24 2001

Keywords

  • Dosimetry
  • Fluorescence
  • Optics
  • PDT
  • Photodynamictherapy
  • Reflectance

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Condensed Matter Physics
  • Computer Science Applications
  • Applied Mathematics
  • Electrical and Electronic Engineering

Fingerprint Dive into the research topics of 'Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT'. Together they form a unique fingerprint.

  • Cite this